Technical Brief
July 2017
Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission—
A Working Group of the Office of AIDS Research Advisory Council (OARAC)
Accessed: 12.02.2020
The goal of this assessment is to determine how far USAID/Senegal’s HIV/AIDS and TB programs have achieved their specific objectives with regard to identifying potential leads for improvement that are likely to make it easier to reach the planned results. After responding to the issues developed i...n various themes of the assessment, the results are placed in context and specific conclusions to each component are provided. The assessment also identifies the lessons learned from USAID/Senegal’s HIV/AIDS and TB programs and provides recommendations for future intervention.
more
Thirty-three years after its discovery, the Human Immunodeficiency Virus (HIV), responsible for the AIDS pandemic, remains a major public health problem despite advanced researches providing better diagnostic and therapeutic tools. The virus targets especially CD4+ T cells, leading to deficiency of ...the immune system and altering therefore defense against infections and cancer cells. Antiretroviral
more
How has the DRC Ebola outbreak impacted Sexual and Reproductive Health in North-Kivu?
Recommendations (more specifics found in the assessment):
1. Sexual and reproductive health needs and services are to be embedded in the EVD response from the outset.
2. Reduce delays at every stage of the patie...nt journey, particularly for women experiencing obstetric complications, including complications from abortion.
3. Support individuals and communities to mitigate SRH risks posed during and after EVD epidemic:
4. Formulate SRH guidelines for the EVD context involving experts in all relevant fields.
more
22nd edition
Each of the 20 chapters deals with aspects of the UHC journey, dedicated towards an equitable and inclusive national health system that leaves no-one behind. While some authors describe the fundamental changes and practical considerations required to reconfigure the country's health sy...stem, others have reflected on specific programmatic areas and have made recommendations from a National Health Insurance (NHI)/UHC lens.
In addition, we are pleased to announce that this year's edition includes two innovations. First is the provision of concise summaries of the chapters in the form of 'chapters at a glance'. These are positioned together at the start of the publication for ease of reference and to give a quick overview. The second innovation is the introduction of our Healthcare Workers' Writing Programme (HCWWP), which provides support to first-time authors wanting to publish in the Review.
more
Der Nationale Pandemieplan besteht aus zwei Teilen. Teil I beschreibt Strukturen und Massnahmen, Teil II stellt die wissenschaftlichen Grundlagen für die Inflünzapandemieplanung und -bewältigung dar. Der vorliegende Teil I wurde von der Arbeitsgruppe Infektionsschutz der Arbeitsgemeinschaft der O...bersten Landesgesundheitsbehörden unter Mitwirkung des Bundesministeriums für Gesundheit, des Robert Koch- Instituts, des Paul-Ehrlich-Instituts und der Bundeszentrale für gesundheitliche Aufklärung erstellt. Er beschreibt die Strukturen auf Bundesund Länderebene, erörtert Massnahmen und gibt Empfehlungen zur Vorbereitung auf eine Inflünzapandemie sowie für die Pandemiebewältigung auf unterschiedlichen Planungs- und Handlungsebenen. Damit dient er als Grundlage für die Pandemieplanung im medizinischen und nichtmedizinischen Bereich und in der öffentlichen Verwaltung.
more
Module 5
Monitoring and Evaluation
October 2018
Module 5: Monitoring and evaluation. This module is for people responsible for monitoring PrEP programmes at the national and site levels. It provides information on how to monitor PrEP for safety and effectiveness, suggesting core and additiona...l indicators for site-level, national and global reporting.
more
This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing thirty key questions about PrEP and how it might be implemented in the UK.
Module 1
Clinical
July 2017
Module 1: Clinical. This module is for clinicians, including physicians, nurses and clinical officers. It gives an overview of how to provide PrEP safely and effectively, including: screening for substantial risk of HIV; performing appropriate testing before initi...ating someone on PrEP and while the person is taking PrEP; and how to follow up PrEP users and offer counselling on issues such as adherence.
more
Module 3
Counsellors
July 2017
Module 3: Counsellors. This module is for staff who counsel people as they consider PrEP or start taking PrEP and support them in coping with side-effects and adherence strategies. Those who counsel PrEP users may be lay, peer or professional counsellors and hea...lthcare workers, including nurses, clinical officers and doctors.
more
Module 4
Leaders
July 2017
Module 4: Leaders. This module aims to inform and update leaders and decision-makers about PrEP. It provides information on the benefits and limitations of PrEP so that they can consider how PrEP could be effectively implemented in their own settings. It also contai...ns a series of frequently asked questions about PrEP.
more
Module 9
Strategic planning
July 2017
Module 9: Strategic planning. As WHO recommends offering PrEP to people at substantial HIV risk, this module offers public health guidance for policy-makers on how to prioritize services, in order to reach those who could benefit most from PrEP, and in wh...ich settings PrEP services could be most cost-effective.
more
Module 10
Testing providers
July 2017
Module 10: Testing providers. This module is for people who provide testing services at PrEP sites and laboratories. It offers guidance in selecting testing services, including screening of individuals before PrEP is initiated and monitoring while they ar...e taking PrEP. Information is provided on HIV testing, creatinine, HBV and HCV, pregnancy and STIs.
more